Ark Biosciences to Present Efficacy Data on Novel Ziresovir at an International Conference
Ark Biosciences (Ark) to present efficacy data on its novel RSV F-protein inhibitor, Ziresovir (AK0529) at the 11th International RSV Symposium in Asheville, North Carolina, USA, 31st October – 4th November 2018
Ark has submitted an abstract reporting single dose clinical efficacy of its novel RSV F-protein inhibitor Ziresovir, formerly known as AK0529, in infants hospitalized for lower respiratory tract infection with naturally acquired RSV infection. The data to be presented is from the Phase II ‘VICTOR (Viral Inhibition in Children for Treatment of RSV)’ study, “A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalised Infants with Respiratory Syncytial Virus Infection”.
Popular recommendations
-
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention2026-10-13
-
ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial2026-08-14
-
ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis2026-08-13
-
ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK04062026-07-24
-
ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK04062026-04-10
-
ArkBio Publishes the Molecular Mechanism of Ziresovir for Treatment of RSV in “PLOS Pathogens”2026-03-23
